Professional background
Dr Henry Mandeville is a consultant clinical oncologist specialising in the treatment of malignancies in children and young people. He qualified from the University of Aberdeen in 1997, and trained in Clinical Oncology in London, at St Bartholomew's and Hammersmith Hospitals. In 2011 he was awarded an MD(Res) from UCL following a Cancer Research UK clinical research fellowship at Mount Vernon Hospital and the Gray Cancer Institute. He specialised in paediatric radiotherapy working at University College Hospital and Great Ormond Street Hospital.
Since December 2011, he has worked as a consultant clinical oncologist in the children and young people’s unit and the haemato-oncology unit at The Royal Marsden Hospital. In May 2024 he was appointed as a consultant paediatric and adolescent clinical oncologist at the UCLH Proton Beam Therapy Centre.
Specialties
Research interests
Currently, his main research interests are in technical radiotherapy improvements for tumours in children and young people. These include: respiratory-related motion management, rotational intensity-modulated radiation therapy (IMRT), MRI-guided radiotherapy and proton beam therapy, and also the impact of local therapy on the quality of life of survivors.
Dr Mandeville has been the Chair of the European Paediatric Soft Tissue Sarcoma Group (EpSSG) Radiotherapy Committee from 2013- 2020 and was on the EpSSG Board from 2018- 2024. He is the Local Therapy lead for the new EpSSG Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) study, and the Chair of the NCRI Young Onset Soft Tissue Sarcoma Subgroup.